Vol. 6 No. 2 (2026)
Reimbursement Reviews

Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)

decorative image of the issue cover

Published February 11, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Nivolumab (Opdivo), 10 mg/mL, single-use vials, IV infusion; and ipilimumab (Yervoy), 5 mg/mL, single-use vials, IV infusion.
  • Indication: Opdivo (nivolumab), in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.